The etiology of dry eye disease (DED) is complex and not yet fully understood, but the
disease is now recognized as being associated with ocular surface inflammation. The latest …

Dry eye disease (DED) is a multifactorial disorder of the ocular surface characterized by
symptoms of discomfort, decreased tear quality, and chronic inflammation that affects an …

Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe
disability, especially in the elderly age group. The mainstay of therapy includes artificial …

Purpose Lifitegrast is an integrin antagonist that decreases T-cell–mediated inflammation
associated with dry eye disease (DED). We report the results of OPUS-2, a phase III study …

Dry eye disease (DED) is a common ocular disorder associated with inflammation of the
lacrimal gland and ocular surface. The interaction of the integrin lymphocyte function …

Purpose Lifitegrast is a lymphocyte function–associated antigen-1 antagonist developed to
reduce inflammation in dry eye disease (DED). We report the results of OPUS-3 …

Dry eye (DE) is a chronic ocular condition with high prevalence and morbidity. It has a
complex pathophysiology and is multifactorial in nature. Chronic ocular surface inflammation …

The objective of this article is to review the pharmacology, efficacy, and safety of lifitegrast
and determine its role relative to other agents in the management of dry eye disease. A …

Clinical and laboratory studies performed over the past few decades have discovered that
dry eye is a chronic inflammatory disease that can be initiated by numerous extrinsic or …

PURPOSE: To investigate the efficacy and safety of an investigational integrin antagonist
(SAR 1118) ophthalmic solution compared to placebo (vehicle) in subjects with dry eye …